TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

Ioka Tatsuya; Ueno Makoto; Ueno Hideki; Park Joon Oh; Chang Heung-Moon; Sasahira Naoki; Kanai Masashi; Chung Ik Joo; Ikeda Masafumi; Nakamori Shoji; Mizuno Nobumasa; Omuro Yasushi; Yamaguchi Taketo; Hara Hiroki; Sugimori Kazuya; Furuse Junji; Maguchi Hiroyuki; Furukawa Masayuki; Fukuzawa Kengo; Kim Jun-Suk; Yukisawa Seigo; Takeuchi Masahiro; Okusaka Takuji; Boku Narikazu; Hyodo Ichinosuke

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

【24h】

TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

机译：TAS-118（S-1加白光伏素）对吉西他滨 - 难治晚期胰腺癌患者的S-1：随机，开放标签，第3阶段研究（葡萄试验）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS).

机译：背景：在我们以前的随机阶段2研究吉西他滨 - 难治晚期胰腺癌患者的研究，S-1加白光素与单独的S-1相比，改善了无进展的存活。在此，我们评估了总存活（OS）中Tas-118（S-1 Plus Leucovorin）对S-1的功效。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共11页
作者
Ioka Tatsuya; Ueno Makoto; Ueno Hideki; Park Joon Oh; Chang Heung-Moon; Sasahira Naoki; Kanai Masashi; Chung Ik Joo; Ikeda Masafumi; Nakamori Shoji; Mizuno Nobumasa; Omuro Yasushi; Yamaguchi Taketo; Hara Hiroki; Sugimori Kazuya; Furuse Junji; Maguchi Hiroyuki; Furukawa Masayuki; Fukuzawa Kengo; Kim Jun-Suk; Yukisawa Seigo; Takeuchi Masahiro; Okusaka Takuji; Boku Narikazu; Hyodo Ichinosuke;
展开▼
作者单位

Osaka Int Canc Inst Dept Canc Survey &

Gastrointestinal Oncol Osaka Japan;

Kanagawa Canc Ctr Dept Gastroenterol Hepatobiliary &

Pancreat Med Oncol Div Yokohama Kanagawa;

Natl Canc Ctr Dept Hepatobiliary &

Pancreat Oncol Tokyo Japan;

Sungkyunkwan Univ Sch Med Samsung Med Ctr Dept Med Seoul South Korea;

Univ Ulsan Coll Med Asan Med Ctr Dept Oncol Seoul South Korea;

Japanese Fdn Canc Res Canc Inst Hosp Dept Gastroenterol Tokyo Japan;

Kyoto Univ Hosp Dept Clin Oncol Kyoto Japan;

Chonnam Natl Univ Hwasun Hosp Dept Hematol Oncol Hwasun South Korea;

Natl Canc Ctr Hosp East Dept Hepatobiliary &

Pancreat Oncol Kashiwa Chiba Japan;

Natl Hosp Org Osaka Natl Hosp Dept Hepatobiliary &

Pancreat Surg Osaka Japan;

Aichi Canc Ctr Hosp Dept Gastroenterol Nagoya Aichi Japan;

Tokyo Metropolitan Canc &

Infect Dis Ctr Komagome Dept Med Oncol Tokyo Japan;

Chiba Canc Ctr Dept Gastroenterol Chiba Japan;

Saitama Canc Ctr Hosp Dept Gastroenterol Saitama Japan;

Yokohama City Univ Med Ctr Gastroenterol Ctr Yokohama Kanagawa Japan;

Kyorin Univ Fac Med Dept Med Oncol Tokyo Japan;

Teine Keijinkai Hosp Ctr Gastroenterol Sapporo Hokkaido Japan;

Natl Hosp Org Kyushu Canc Ctr Dept Hepatobiliary Pancreatol Fukuoka Fukuoka Japan;

Oita Red Cross Hosp Dept Surg Oita Japan;

Korea Univ Guro Hosp Dept Hematol &

Oncol Seoul South Korea;

Tochigi Canc Ctr Dept Med Oncol Utsunomiya Tochigi Japan;

Kitasato Univ Sch Pharm Biostat Dept Clin Med Tokyo Japan;

Natl Canc Ctr Dept Hepatobiliary &

Pancreat Oncol Tokyo Japan;

Natl Canc Ctr Div Gastrointestinal Med Oncol Tokyo Japan;

Univ Tsukuba Fac Med Dept Gastroenterol 1-1-1 Tennodai Tsukuba Ibaraki 3058575 Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Pancreatic cancer; TAS-118; S-1; Leucovorin; Fluorouracil; Second-line chemotherapy;

机译：胰腺癌;TAS-118;S-1;Leucovorin;氟尿嘧啶;二线化疗;

相似文献

外文文献
中文文献

1. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial) [J] . Ioka Tatsuya, Ueno Makoto, Ueno Hideki, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：TAS-118（S-1加白光伏素）对吉西他滨 - 难治晚期胰腺癌患者的S-1：随机，开放标签，第3阶段研究（葡萄试验）
2. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer [J] . Ueno M., Okusaka T., Omuro Y., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第3期

机译：S-1加口服亚叶酸钙与S-1单药治疗吉西他滨难治性晚期胰腺癌的随机II期研究
3. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, Multicenter, Phase II study [J] . GeF., XuN., BaiY., The oncologist . 2014,第11期

机译：S-1单药治疗或联合亚叶酸治疗二线治疗吉西他滨难治性晚期胰腺癌：一项随机，开放标签，多中心，II期研究
4. S-1/CDDP/Lentinan Combination Chemotherapy for Inoperable Advanced Gastric Cancer [C] . Shoichi Nagahashi, Hidekazu Suzuki, Toshifumi Hib International Gastric Cancer Congress . 2005

机译：S-1 / CDDP / Lentinan组合化疗，可管理的胃癌无法操作
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer [O] . M. Ueno, T. Okusaka, Y. Omuro, -1

机译：S-1加口服亚叶酸钙与S-1单药治疗吉西他滨难治性晚期胰腺癌的II期随机研究
7. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway [O] . 2017

机译：S-1加亚叶酸钙在晚期胃癌患者中的II期试验以及通过S-1药物遗传学途径进行的临床预测

TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

摘要

著录项

相似文献

相关主题

期刊订阅